FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.
What happened
FDA inspected the facility from October 14 to 18, 2024. The agency found repeated out-of-limit microbial results in a component system used to make drug products, inadequate investigations of those results, missing identity testing for each component lot including an active ingredient, and laboratory computer systems without sufficient access controls or backups.
What FDA found
The firm did not thoroughly investigate repeated out-of-limit microbial results in a component system used to make drug products, and its investigations lacked root cause determinations, effective corrective actions, and assessment of all affected batches.
21 CFR 211.192The firm did not test each component lot, including an active ingredient, for identity and other specifications, and it relied on supplier certificates of analysis without establishing the suppliers' test reliability.
21 CFR 211.84(d)(1) and 211.84(d)(2)Laboratory computer systems lacked unique usernames and passwords and enough controls to prevent deletion or modification of HPLC, GC, and FTIR data, and backups were inadequate.
21 CFR 211.68(b)
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with comprehensive assessments, risk evaluations, corrective action plans, and supporting documents. If it cannot finish in that time, it must explain the delay and give a schedule.
Who should pay attention
- companies that buy or distribute drugs made at this site
- brands selling over-the-counter drugs made with components from this site
- quality teams that rely on supplier certificates of analysis for incoming components
This is a summary. Read the original letter on fda.gov.